Navigation Links
Biosimilars Market worth $1,954 Million by 2018
Date:11/18/2013

DALLAS, November 18, 2013 /PRNewswire/ --

The "Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global Biosimilars Market along with the estimates and forecasts of the revenue and share analysis.

Browse 80 market data tables and 80 figures spread through 320 pages and in-depth TOC on "Biosimilars Market".

http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

Early buyers will receive 10% customization on this report.

The global Biosimilars Market is segmented on the basis of products, applications, and services. By product, the global Biosimilars Market is further segmented into recombinant non-glycosylated proteins (insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone), recombinant glycosylated proteins (erythropoietin, monoclonal antibodies, and follitropin), and recombinant peptides (glucagon and calcitonin). The recombinant glycosylated proteins segment is the largest segment and accounts for a share of 40% of the global Biosimilars Market in 2013 at an estimated $314.2 million and is expected to grow at a CAGR of 17.5% from 2013 to 2018. The biggest factor behind the growth of this segment is the increasing demand for second-wave Biosimilar products, such as insulin and interferon, for the treatment of diabetes and infectious disorders.  Of all segments under the product category, the monoclonal antibodies segment is the fastest-growing segment at an estimated CAGR of more than 40% from 2013 to 2018.

By application, oncology is the largest and fastest-growing segment and accounts for a share of 25% of the global Biosimilars Market. This is attributed to the increasing prevalence of oncology along with the rise in aging population and the changing lifestyle.

Europe dominates the global Biosimilars Market with around 40% share in 2013. The factors driving the European market are its well-defined regulatory guidelines; presence of various Biosimilar drugs such as omnitrope, tevagrastim, and binocrits; numerous pipeline products; and more than 15 biologics going off-patent in the coming years. Although the penetration of Biosimilars varies by country, it also depends on various other factors, including local pricing and reimbursement policies, stakeholder influence, and attitudes towards the adoption and use of Biosimilars. Currently, Germany commands the highest share in the European market due to the presence of a reference pricing system.

The U.S., on the other hand, has a very restricted Biosimilars Market owing to the stringent regulatory environment in North America. The Asia-Pacific market is estimated to be the fastest-growing market. Asia-Pacific accounts for an overall share of 29% of the global Biosimilars Market. This large share of the market is mainly due to the semi-regulatory environment of the region that easily approves similar biologics in the market. In addition, low manufacturing costs and the presence of highly skilled expertise at low costs are also factors that make Asia-Pacific a lucrative destination for the Biosimilars Market.

The factors restricting the growth of the market are high manufacturing complexities and costs, stringent regulatory environment in the U.S. and Europe, innovative strategies used by biologic drug manufacturers to protect their intellectual property, costly purification process, arrival of biobetters, and the presence of low-priced biogenerics that compete with Biosimilars in the market.

The key players in the Biosimilars Market are Sandoz (Germany), Hospira (U.S.), Teva (Israel), Dr. Reddy's Laboratories (India), Biocon Ltd. (India), Mylan (U.S.), Biopartners (Switzerland), Amgen (U.S.), Intas Biopharmaceultical Ltd. (India), and Innovent Biologics, Inc. (U.S.). In 2013, Sandoz is the highest contributor (50%) to the global Biosimilars Market.

Browse related reports

Pharmaceutical Excipients Market [By Products (Carbohydrates, Oleochemicals, Petrochemicals, Polymers, Microcrystalline Cellulose, Sugar, Calcium carbonate), By Functionality (Fillers, Binders, Lubricants, Preservatives)] - Global Forecast to 2018

 http://www.marketsandmarkets.com/Market-Reports/pharma-excipients-market-956.html

Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017

http://www.marketsandmarkets.com/Market-Reports/drug-delivery-technologies-market-1085.html 

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, agriculture industry, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
2. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
3. Biosimilars: Global Markets
4. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
5. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
6. Biosimilars Market Expected to Soar
7. Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
8. XBiotech Expands Portfolio to Include Biosimilars
9. Recall of Anemia Drug Omontys Rings Alarm Over Biosimilars
10. Seminar Spotlights Key Trends in Biologics and Biosimilars
11. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... NEW YORK , May 26, 2016 ... industry, investors see value in this space. Today,s pre-market research ... Healthcare equities: Radius Health Inc. (NASDAQ: RDUS ), ... (NASDAQ: ARWR ), and Five Prime Therapeutics Inc. ... these stock technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder Scientific (KinderScientific.com), ... developments that position the Company for the future. Kinder Scientific announces restructured ... Kinghorn has been appointed Chairman of the Board, Curtis D. Kinghorn has been ...
(Date:5/25/2016)... Diego, Calif. (PRWEB) , ... May 25, 2016 , ... ... Diego area and has consistently been rated one of its top attractions. Fortune ... the globe to participate in a unique and intimate team-building experience. , Each event ...
Breaking Biology Technology:
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):